NAASO-The Obesity Society 2007 Leadership
A Panel Discussion Among Eight Key Opinion Leaders in Obesity Medicine
Deliverable: Panel transcript with key findings.
Study Description and Objectives
Panel Intelligence conducted an on-line discussion among eight specialists in Obesity Medicine regarding information presented at the NAASO – The Obesity Society 2007 annual meeting. The objectives of the panel follow:
§ Review current treatment practices for the pharmacological treatment of obesity.
§ Assess the use of OTC Orlistat.
§ Discuss the use of Pramlintide and Exenatide in the treatment of obesity.
§ Analyze potential combination therapies including:
o Phentermine and Topiramate.
o Zonisamide and Bupropion.
o Naltrexone and Bupropion.
§ Review data about Taranabant, a cannabinoid-1 receptor inverse agonist.
§ Examine data about S-2367, a neuropeptide-Y Y5 receptor antagonist.
§ Explore future therapies for obesity that are currently in development.
Companies and Products Mentioned in This Report
|
Company |
Ticker Symbol |
Product(s) |
|
GlaxoSmithKline |
GSK |
AlliTM (Orlistat) |
|
Roche Laboratories, Inc. |
RO.S |
XenicalÒ (Orlistat) |
|
Amylin Pharmaceuticals, Inc. |
AMLN |
ByettaÒ (Exenatide) SymlinÒ (Pramlintide) |
|
Eli Lilly and Company |
LLY |
ByettaÒ (Exenatide) |
|
|
|
Phentermine |
|
Ortho-McNeil Neurologics, Inc |
|
TopamaxÒ (Topiramate) |
|
Eisai, Inc. |
ESALF.PK |
ZonegranÒ (Zonisamide) |
|
Glaxo Smith Kline |
GSK |
Wellbutrin (Bupropion) |
|
Merck |
MRK |
Taranbant |
|
Sanofi-Aventis |
SNY |
Rimonabant |
|
Shionogi & Co, Ltd |
SGIOF.PK |
S-2367 |
Inclusion Criteria
|
Inclusion Criteria
|
§ Key opinion leader in obesity medicine § Board-certified in area of specialty § 2-30 years of experience post-training § Request disclosure of past and current consulting relationships |
Hospitals Represented
|
Hospital/Academic Affiliation |
State |
|
|
MA |
|
Charite Campus Benjamin Franklin |
|
|
|
|
|
|
CO |
|
|
MA |
|
Storch Medical Nutrition Associates |
PA |
|
|
CA |
| © Panel Intelligence, LLC. 1999-2008. All rights reserved. A wholly owned subsidiary of MCF Corporation (NASDAQ: MERR) Privacy Policy |